An HDE is an application similar to a PMA but exempt from the effectiveness requirements. It allows marketing of a Humanitarian Use Device (HUD) intended to benefit patients with rare diseases or conditions. HUD designation from FDA's Office of Orphan Products Development comes first, for a condition affecting not more than 8,000 people in the US per year. The application must show probable benefit outweighing risk, and use is overseen by an institutional review board. Profit limits apply, with exceptions for certain pediatric devices.

Why it matters

HDE devices must demonstrate probable benefit outweighs risk of injury or illness. Use is generally restricted, often requiring IRB oversight, and there are profit limitations except in pediatric cases.

Common pitfalls

•A common misconception is that HDE devices do not require clinical data; however, clinical data is necessary to demonstrate probable benefit and assess risks.
•Failing to understand the profit limitations for HDE devices, which generally cap annual sales, can lead to compliance issues.
•Manufacturers sometimes overlook the ongoing post-approval requirements, including reporting adverse events and changes to the device.
•Confusing the HDE process with other regulatory pathways, such as 510(k) or PMA, can lead to incorrect application strategies.

Sources

Humanitarian Device Exemption · FDA
European Commission - Medical Devices · European Commission
IMDRF Documents · IMDRF

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.